NCT04856644View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

333

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions
Tuberculosis, Pulmonary
Interventions
DRUG

4-month rifapentine-based regimen

8 weeks of isoniazid, pyrazinamide, rifapentine, and moxifloxacin, followed by 9 weeks of isoniazid, rifapentine and moxifloxacin

Trial Locations (4)

112

Taipei Veterans General Hospital, Taipei

333

Linkou Chang Gung Memorial Hospital, Taoyuan

813

Kaohsiung Veterans General Hospital, Kaohsiung City

Unknown

National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

National Taiwan University

OTHER

collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

Centers for Disease Control, Taiwan

OTHER_GOV

lead

Kaohsiung Veterans General Hospital.

OTHER

NCT04856644 - Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB | Biotech Hunter | Biotech Hunter